Current and next generation antimitotic therapies in cancer

Signaling Pathways in Cancer Pathogenesis and Therapy

Volumn , Issue , 2012, Pages 5-21

  Ecsedy, Jeffrey A ^a   Manfredi, Mark ^a   Chakravarty, Arijit ^a   D'Amore, Natalie ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949178843     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1216-8_2     Document Type: Chapter

References (121)

1. Abend M (2003) Reasons to reconsider the signifi cance of apoptosis for cancer therapy. Int J Radiat Biol 79:927-941
2. Adams RR, Maiato H, Earnshaw WC, Carmena M (2001) Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Cell Biol 153:865-880
3. Andresson T, Ruderman JV (1998) The kinase Eg2 is a component of the Xenopus oocyte progesterone-activated signaling pathway. EMBO J 17:5627-5637
4. Barr AR, Gergely F (2007) Aurora-A: the maker and breaker of spindle poles. J Cell Sci 120:2987-2996
5. Bischoff JR, Plowman GD (1999) The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 9:454-459
6. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C et al (1998) A homologue of Drosophila aurora kinase is oncogenic and amplifi ed in human colorectal cancers. EMBO J 17:3052-3065
7. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333
8. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL et al (2003) Trastuzumab and vinorelbine as fi rst-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895
9. Camacho E, Bea S, Salaverria I, Lopez-Guillermo A, Puig X, Benavente Y, de Sanjose S, Campo E, Hernandez L (2006) Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma. Int J Cancer 118:357-363
10. Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842-854
11. Chakravarty, A., Shinde, V., Galvin, K., Bowman, D., Stringer, B., Danaee, H., Venkatakrishnan, K., Simpson, C., Farron-Yowe, L., Liu, H., et al. (2010). Phase I Assessment of Mechanistic Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase. Submitted for publication
12. Chan CS, Botstein D (1993) Isolation and characterization of chromosome-gain and increase-inploidy mutants in yeast. Genetics 135:677-691
13. Chen JG, Horwitz SB (2002) Differential mitotic responses to microtubule-stabilizing and-destabilizing drugs. Cancer Res 62:1935-1938
14. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz M. A, Lacy MQ, Dispenzieri A, Kumar S, Rajkumar SV et al (2006) Clinical implication of centrosome amplifi cation in plasma cell neoplasm. Blood 107:3669-3675
15. Dalton WB, Nandan MO, Moore RT, Yang VW (2007) Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res 67:11487-11492
16. Dietzmann K, Kirches E, Tighe A, von B, Jachau K, Mawrin C (2001) Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 53:1-11
17. Ditchfi eld C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161:267-280
18. Dutertre S, Hamard-Peron E, Cremet JY, Thomas Y, Prigent C (2005) The absence of p53 aggravates polyploidy and centrosome number abnormality induced by Aurora-C overexpression. Cell Cycle 4:1783-1787
19. Eckerdt F, Strebhardt K (2006) Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res 66:6895-6898
20. Elia AE, Cantley LC, Yaffe MB (2003a) Proteomic screen fi nds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 299:1228-1231
21. Elia AE, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K, Mohammad D, Cantley LC, Smerdon SJ, Yaffe MB (2003b) The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 115:83-95
22. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S (2004) Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25:1631-1639
23. Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM, Tindal DJ, Chen J (2008) Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol 10:1076-1082
24. Fumoleau P, Coudert B, Isambert N, Ferrant E (2007) Novel tubulin-targeting agents: anticancer activity and pharmacologic profi le of epothilones and related analogues. Ann Oncol 18(Suppl 5):v9-v15
25. Gan Y, Wientjes MG, Lu J, Au JL (1998) Cytostatic and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother Pharmacol 42:177-182
26. Gascoigne KE, Taylor SS (2008) Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14:111-122
27. Giet R, Glover DM (2001) Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J Cell Biol 152:669-682
28. Giet R, Petretti C, Prigent C (2005) Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol 15:241-250
29. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond M. A, Jackson JR, Laquerre SG (2009) Distinct concentration-dependent effects of the polo-like kinase 1-specifi c inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 69:6969-6977
30. Glover DM, Leibowitz MH, McLean DA, Parry H (1995) Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 81:95-105
31. Goepfert TM, Adigun YE, Zhong L, Gay J, Medina D, Brinkley WR (2002) Centrosome amplifi-cation and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res 62:4115-4122
32. Gonzalez-Angulo AM, Hortobagyi GN (2008) Optimal schedule of paclitaxel: weekly is better. J Clin Oncol 26:1585-1587
33. Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD (2004) Identifi cation of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 3:641-646
34. Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK et al (2007) Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res 67:10436-10444
35. Harrison MR, Holen KD, Liu G (2009) Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 7:54-64
36. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161:281-294
37. Hernandez-Vargas H, Palacios J, Moreno-Bueno G (2007a) Telling cells how to die: docetaxel therapy in cancer cell lines. Cell Cycle 6:780-783
38. Hernandez-Vargas H, von Kobbe C, Sanchez-Estevez C, Julian-Tendero M, Palacios J, Moreno-Bueno G (2007b) Inhibition of paclitaxel-induced proteasome activation infl uences paclitaxel cytotoxicity in breast cancer cells in a sequence-dependent manner. Cell Cycle 6:2662-2668
39. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy D'Amore N, Ecsedy JA (2007) MLN8054, a small molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 27:4513-4525
40. Honda R, Korner R, Nigg EA (2003) Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14:3325-3341
41. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044
42. Ikezoe T, Yang J, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffl er HP, Taguchi H (2007) A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 6:1851-1857
43. Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L (2002) Phase II trial of weekly vinorelbine and trastuzumab as fi rst-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 7:410-417
44. Jeng YM, Peng SY, Lin CY, Hsu HC (2004) Overexpression and amplifi cation of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10:2065-2071
45. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551
46. Kaestner P, Stolz A, Bastians H (2009) Determinants for the effi ciency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 8:2046-2056
47. Kanaji S, Saito H, Tsujitani S, Matsumoto S, Tatebe S, Kondo A, Ozaki M, Ito H, Ikeguchi M (2006) Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 70:126-133
48. Katayama H, Zhou H, Li Q, Tatsuka M, Sen S (2001) Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle. J Biol Chem 276:46219-46224
49. Kelling J, Sullivan K, Wilson L, Jordan M. A (2003) Suppression of centromere dynamics by Taxol in living osteosarcoma cells. Cancer Res 63:2794-2801
50. Kimura M, Matsuda Y, Yoshioka T, Okano Y (1999) Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 274:7334-7340
51. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K (1999) Prognostic signifi-cance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59:2794-2797
52. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R (2002) Expression of pololike kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 29:354-358
53. Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purifi ed tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272:2534-2541
54. Krikorian A, Breillout F (1991) Vinorelbine (Navelbine). A new semisynthetic vinca alkaloid. Onkologie 14:7-12
55. Kumagai A, Dunphy WG (1996) Purifi cation and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273:1377-1380
56. Landen CN Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK (2007) Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 13:4098-4104
57. Lane HA, Nigg EA (1996) Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135:1701-1713
58. Lee KS, Grenfell TZ, Yarm FR, Erikson RL (1998) Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc Natl Acad Sci USA 95:9301-9306
59. Lei M, Erikson RL (2008) Plk1 depletion in nontransformed diploid cells activates the DNAdamage checkpoint. Oncogene 27:3935-3943
60. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM (2007) The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 17:304-315
61. Li H, Wang Y, Liu X (2008) Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. J Biol Chem 283:6209-6221
62. Li CC, Chu HY, Yang CW, Chou CK, Tsai TF (2009) Aurora-A overexpression in mouse liver causes p53-dependent premitotic arrest during liver regeneration. Mol Cancer Res 7:678-688
63. Liu X, Erikson RL (2002) Activation of Cdc2/cyclin B and inhibition of centrosome amplifi cation in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA 99:8672-8676
64. Liu X, Erikson RL (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100:5789-5794
65. Llamazares S, Moreira A, Tavares A, Girdham C, Spruce BA, Gonzalez C, Karess RE, Glover DM, Sunkel CE (1991) Polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev 5:2153-2165
66. Marumoto T, Hirota T, Morisaki T, Kunitoku N, Zhang D, Ichikawa Y, Sasayama T, Kuninaka S, Mimori T, Tamaki N et al (2002) Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 7:1173-1182
67. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, Saya H (2003) Aurora-A kinase maintains the fi delity of early and late mitotic events in HeLa cells. J Biol Chem 278: 51786-51795
68. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88:1308-1314
69. Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I, Yokoyama S (2005) Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 46:225-231
70. Miyoshi Y, Iwao K, Egawa C, Noguchi S (2001) Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92:370-373
71. Murata-Hori M, Wang YL (2002) The kinase activity of aurora B is required for kinetochoremicrotubule interactions during mitosis. Curr Biol 12:894-899
72. Neef R, Gruneberg U, Kopajtich R, Li X, Nigg EA, Sillje H, Barr FA (2007) Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1. Nat Cell Biol 9:436-444
73. Orth JD, Tang Y, Shi J, Loy CT, Amendt C, Wilm C, Zenke FT, Mitchison TJ (2008) Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates signifi cant differences in phenotypic responses and cell fate. Mol Cancer Ther 7:3480-3489
74. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN (2007) Effi cacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414
75. Peters U, Cherian J, Kim JH, Kwok BH, Kapoor TM (2006) Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2:618-626
76. Petronczki M, Glotzer M, Kraut N, Peters JM (2007) Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. Dev Cell 12:713-725
77. Quignon F, Rozier L, Lachages AM, Bieth A, Simili M, Debatisse M (2007) Sustained mitotic block elicits DNA breaks: one-step alteration of ploidy and chromosome integrity in mammalian cells. Oncogene 26:165-172
78. Rieder CL, Maiato H (2004) Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 7:637-651
79. Roghi C, Giet R, Uzbekov R, Morin N, Chartrain I, Le Guellec R, Couturier A, Doree M, Philippe M, Prigent C (1998) The Xenopus protein kinase pEg2 associates with the centrosome in a cell cycle-dependent manner, binds to the spindle microtubules and is involved in bipolar mitotic spindle assembly. J Cell Sci 111(Pt 5):557-572
80. Roninson IB, Broude EV, Chang BD (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4:303-313
81. Rubin EH, Rothermel J, Tesfaye F, Chen T, Hubert M, Ho YY, Hsu CH, Oza AM (2005) Phase I dose-fi nding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 23:9120-9129
82. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profi le and broad antitumor activity. Clin Cancer Res 15:3094-3102
83. Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, Shimomura K, Nakamura Y, Inazawa J, Abe T, Yamagishi H (2001) Tumour-amplifi ed kinase BTAK is amplifi ed and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84:824-831
84. Salminen E, Bergman M, Huhtala S, Ekholm E (1999) Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. J Clin Oncol 17:1127
85. Sasai K, Katayama H, Stenoien DL, Fujii S, Honda R, Kimura M, Okano Y, Tatsuka M, Suzuki F, Nigg EA et al (2004) Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 59:249-263
86. Sasai K, Parant JM, Brandt ME, Carter J, Adams HP, Stass SA, Killary AM, Katayama H, Sen S (2008) Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene 27:4122-4127
87. Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fi broblast cells. Proc Natl Acad Sci USA 77:1561-1565
88. Schimming R, Mason KA, Hunter N, Weil M, Kishi K, Milas L (1999) Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 43:165-172
89. Schoffski P (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14:559-570
90. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: fi nal results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649
91. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC et al (2002) Amplifi cation/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320-1329
92. Sessa C, Perotti A, Llado A, Cresta S, Capri G, Voi M, Marsoni S, Corradino I, Gianni L (2007) Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 18:1548-1553
93. Shi J, Orth JD, Mitchison T (2008) Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68:3269-3276
94. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, Ferris DK (1997) Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 234:397-405
95. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH (2000) Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2:672-676
96. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K (2004) Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96:862-872
97. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94:1863-1877
98. Sumara I, Gimenez-Abian JF, Gerlich D, Hirota T, Kraft C, de la Torre C, Ellenberg J, Peters JM (2004) Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 14:1712-1722
99. Sunkel CE, Glover DM (1988) Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J Cell Sci 89:25-38
100. Svendsen JM, Smogorzewska A, Sowa ME, O'Connell BC, Gygi SP, Elledge SJ, Harper JW (2009) Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 138:63-77
101. Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P et al (2000) Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fi ne-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 6:4610-4617
102. Takahashi T, Futamura M, Yoshimi N, Sano J, Katada M, Takagi Y, Kimura M, Yoshioka T, Okano Y, Saji S (2000) Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 91:1007-1014
103. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S (2003) Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94:148-152
104. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I (2001) Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 169:41-49
105. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217
106. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y (1999) Prognostic signifi cance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 15:687-692
107. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E (2001) Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410:215-220
108. [erratum appears in Nature, 2001 Apr 12;410(6830):847]
109. Tseng TC, Chen SH, Hsu YP, Tang TK (1998) Protein kinase profi le of sperm and eggs: cloning and characterization of two novel testis-specifi c protein kinases (AIE1, AIE2) related to yeast and fl y chromosome segregation regulators. DNA Cell Biol 17:823-833
110. van Vugt M. A, Bras A, Medema RH (2004) Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell 15:799-811
111. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, Deng CX (2006a) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25:7148-7158
112. Wang XX, Liu R, Jin SQ, Fan FY, Zhan QM (2006b) Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. Cell Res 16:356-366
113. Wartmann M, Altmann KH (2002) The biology and medicinal chemistry of epothilones. Curr Med Chem 2:123-148
114. Watkins EB, Chittiboyina AG, Jung JC, Avery M. A (2005) The epothilones and related analogues-a review of their syntheses and anti-cancer activities. Curr Pharm Des 11:1615-1653
115. Weaver BAA, Cleveland DW (2005) Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation and cell death. Cancer Cell 8:7-12
116. Winkles JA, Alberts GF (2005) Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24:260-266
117. Wu ZQ, Yang X, Weber G, Liu X (2008) Plk1 phosphorylation of TRF1 is essential for its binding to telomeres. J Biol Chem 283:25503-25513
118. Yamamoto Y, Matsuyama H, Kawauchi S, Matsumoto H, Nagao K, Ohmi C, Sakano S, Furuya T, Oga A, Naito K, Sasaki K (2006) Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 70:231-237
119. Yokoyama T, Goto H, Izawa I, Mizutani H, Inagaki M (2005) Aurora-B and Rho-kinase/ROCK, the two cleavage furrow kinases, independently regulate the progression of cytokinesis: possible existence of a novel cleavage furrow kinase phosphorylates ezrin/radixin/moesin (ERM). Genes Cells 10:127-137
120. Zhang D, Shimizu T, Araki N, Hirota T, Yoshie M, Ogawa K, Nakagata N, Takeya M, Saya H (2008) Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-defi cient mice. Oncogene 27:4305-4314
121. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplifi ed kinase STK15/BTAK induces centrosome amplifi cation, aneuploidy and transformation. Nat Genet 20:189-193